查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830504

疼痛管理治疗市场（按药物类别、给药途径、适应症、分销管道和最终用户划分）—2025-2032 年全球预测

Pain Management Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年疼痛管理治疗市场将成长至 1,267.5 亿美元，复合年增长率为 4.89%。

主要市场统计数据
基准年2024年 865.1亿美元
预计2025年 906.7亿美元
预测年份：2032年 1267.5亿美元
复合年增长率（%） 4.89%

快速发展的临床、监管和商业环境正在重塑疼痛治疗，需要以证据为导向的相关人员合作策略

在临床创新、监管格局调整以及相关人员期望变化的推动下，疼痛管理治疗领域正在经历快速、多维度的变革。药理学的进步、对鸦片类药物管理的重视以及非药物辅助治疗的加速发展，共同拓展了临床医生可用的治疗套件。因此，治疗模式正在从「一刀切」的方案转变为更个人化、多模态的方案，优先考虑疗效、安全性和功能性结果。

同时，支付方和提供者的框架越来越注重基于以金额为准的护理、疗效衡量和成本控制。这种环境给产品开发商和服务提供者带来压力，他们不仅需要证明临床效益，还需要证明现实世界的疗效和经济价值。监管机构正在采取相应措施，加强对鸦片类药物组合的监测，加强对某些辅助性治疗的监管，并对临床终点提供更清晰的指导。

从商业性角度来看，打入市场策略现在必须解决更多细分的相关人员，例如综合医疗服务网络、门诊手术中心、居家医疗提供者、数位健康平台等。在此背景下，将临床证据产生与实际部署模型和相关人员特定的价值提案相结合的公司将最有能力影响护理途径并获得持久的采用。

多模态临床实践、数位疗法和弹性供应链融合，重塑治疗模式并加速采用途径

近年来，医疗机构正在重新定义疼痛的治疗、测量和管理方式。临床上，多模态镇痛疗法（结合药物和非药物治疗，以改善疗效并减少阿片类药物暴露）正逐渐获得认可。关于阿片类药物过度依赖的长期危害的新证据，以及奖励患者坚持使用替代药物和治疗途径的支付方政策，进一步强化了这种转变。

技术创新也正在改变治疗格局。利用数位疗法、远端监控、穿戴式感测器和远端医疗的疼痛管理项目，能够持续评估患者报告的治疗结果，并更快速地调整治疗方法。同时，长效注射剂和经皮系统等药物传递技术的进步，正在拓展持续缓解疼痛的选择，并提高患者的依从性。

全球疫情衝击凸显了采购和生产环节的脆弱性，供应链和製造业的韧性已成为策略重点。因此，企业正在重新评估其地理布局，实现供应商多元化，并投资于本土能力，以缓解未来的衝击。这种调整与临床试验设计转向同步进行，这些设计强调可操作的终点、分散的入组和以患者为中心的措施，这些因素共同加速了证据生成和临床应用。

关税驱动的供应链重组、近岸倡议以及付款人成本担忧已经再形成了各行业的营运重点和策略投资

2025年实施的关税及相关贸易措施，为疼痛照护相关人员带来了新的营运和策略考量。对于依赖全球化供应链的製造商而言，关税带来的成本上升促使他们重新评估采购决策、投入替代方案和製造布局。在许多情况下，企业采取的应对措施包括增加库存缓衝、将关键零件转移到其他低成本采购国家，或投资近岸外包倡议，以降低关税波动的影响。

这些营运调整也对产品开发时程和商业策略产生了间接影响。企业优先考虑那些具有韧性和差异化价值的投资，例如先进的给药系统和不易受商品价格波动影响的设备-药物组合。与经销商和付款人的合约谈判现在通常包含关税减免条款和转嫁机制，这些条款正在影响定价讨论和报销谈判。

在临床层面，关税环境强化了成本效益治疗方案的重要性，并加速了支付方对那些能够减少高成本服务使用率的治疗方法的兴趣。因此，能够证明整体医疗成本优势的公司以及提供一体化服务模式的公司拥有谈判优势。整体而言，关税格局正在提升营运敏捷性和供应链透明度，使其成为产业参与者的核心竞争优势。

多维细分框架揭示了整合和定位药物类别、交付方式、适应症、分销管道和最终用户环境的机会

细緻的细分视角对于理解疼痛管理领域临床机会和商业性吸引力的交会点至关重要。依药物类别划分，包括辅助性镇痛药、局部麻醉剂、神经病变疼痛治疗​​药物、非类固醇消炎剂和鸦片类药物。神经病变疼痛治疗​​药物分为抗惊厥药和抗忧郁症，非类固醇类药物分为环氧合酶-2抑制剂和传统非类固醇抗发炎药，鸦片类药物分为强效鸦片类药物和弱效鸦片类药物。每种药物的疗效、安全性和监管特征各不相同，这些都影响着配方师的偏好和报销考量。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 快速采用基于虚拟实境的治疗方法治疗慢性神经病变疼痛
  • 整合式可穿戴生物感测贴片，用于持续监测术后疼痛
  • 针对发炎疼痛途径的个人化基因治疗方法的开发
  • 越来越多地使用数位健康平台来提供针对疼痛的认知行为疗法
  • 微创聚焦超音波在缓解肌肉骨骼疼痛的应用成长
  • 核准用于治疗骨关节炎疼痛的长效非鸦片类注射药物
  • 针对缓解神经病变疼痛的大麻素受体调变器的出现

第六章 2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 疼痛管理治疗市场（依药物类别）

  • 辅助止痛药
  • 局部麻醉剂
  • 神经病变疼痛治疗
    • 抗惊厥药
    • 抗忧郁症
  • 非类固醇消炎剂
    • COX-2抑制剂
    • 传统非类固醇抗发炎药
  • 阿片类药物
    • 强效阿片类药物
    • 弱阿片类药物

9. 疼痛管理治疗市场（依给药途径）

  • 口服
  • 肠外
    • 肌肉注射
    • 静脉
    • 皮下
  • 局部的
  • 经皮

第 10 章疼痛管理治疗市场（按适应症）

  • 急性疼痛
  • 癌症痛
  • 慢性疼痛
    • 下背部疼痛
    • 慢性神经病变疼痛
    • 骨关节炎
    • 类风湿性关节炎
  • 发炎疼痛
  • 神经病变疼痛

第 11 章疼痛管理治疗市场（依通路）

  • 离线
  • 在线的

第 12 章：疼痛管理治疗市场（以最终用户划分）

  • 门诊手术中心
  • 居家照护
    • 安宁疗护
    • 病人家
  • 医院
    • 私立医院
    • 公立医院

第十三章疼痛管理治疗市场：按地区

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章疼痛管理治疗市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 疼痛管理治疗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • Bayer AG
    • GlaxoSmithKline plc
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Endo International plc
    • Mallinckrodt plc
    • AstraZeneca plc
Product Code: MRR-431388EE3C5C

The Pain Management Therapeutics Market is projected to grow by USD 126.75 billion at a CAGR of 4.89% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 86.51 billion
Estimated Year [2025] USD 90.67 billion
Forecast Year [2032] USD 126.75 billion
CAGR (%) 4.89%

A rapidly evolving clinical, regulatory, and commercial environment reshapes pain therapeutics and requires evidence-driven, stakeholder-aligned strategies

The pain management therapeutics landscape is undergoing a rapid, multi-dimensional evolution driven by clinical innovation, regulatory recalibration, and shifting stakeholder expectations. Advances in pharmacology, greater emphasis on opioid stewardship, and the acceleration of nonpharmacologic adjuncts have collectively broadened the therapeutic toolkit available to clinicians. As a result, treatment paradigms are moving away from one-size-fits-all regimens toward more individualized, multimodal approaches that prioritize efficacy, safety, and functional outcomes.

Simultaneously, payer and provider frameworks are increasingly focused on value-based care, outcome measurement, and cost containment. This environment compels product developers and service providers to substantiate not only clinical benefits but also real-world effectiveness and economic value. Regulatory bodies are responding with enhanced oversight of opioid prescribing, tighter controls around certain adjuvant therapies, and clearer guidance on clinical endpoints.

From a commercial perspective, market access strategies must now accommodate a more fragmented set of stakeholders, including integrated delivery networks, ambulatory surgery centers, home care providers, and digital health platforms. In this context, companies that align clinical evidence generation with pragmatic deployment models and stakeholder-specific value propositions will be best positioned to influence care pathways and gain durable adoption.

Multimodal clinical practices, digital therapeutics, and resilient supply chains converge to reshape treatment paradigms and accelerate adoption pathways

Recent years have seen several transformative shifts that are redefining how pain is treated, measured, and managed across care settings. Clinically, there is growing acceptance of multimodal analgesia that combines pharmacologic and nonpharmacologic modalities to improve outcomes while reducing opioid exposure. This shift is reinforced by emerging evidence on the long-term harms of opioid overreliance and by payer policies that incentivize alternatives and pathway adherence.

Technological innovation is also altering the landscape. Digital therapeutics, remote monitoring, wearable sensors, and telehealth-enabled pain management programs are enabling continuous assessment of patient-reported outcomes and facilitating more responsive titration of therapies. In parallel, advances in drug delivery, including long-acting injectables and transdermal systems, are expanding options for sustained analgesia with improved adherence profiles.

Supply chain and manufacturing resilience have become strategic priorities after global disruptions highlighted vulnerabilities in sourcing and production. Companies are therefore reassessing geographic footprints, diversifying supplier bases, and investing in onshore capabilities to mitigate future shocks. This realignment is occurring alongside a shift in clinical trial design that emphasizes pragmatic endpoints, decentralized enrollment, and patient-centric measures, which together accelerate evidence generation and adoption in real-world practice.

Tariff-induced supply chain recalibration, nearshoring initiatives, and payer cost-concerns reshaped operational priorities and strategic investments across the industry

The imposition of tariffs and related trade measures in 2025 introduced a new set of operational and strategic considerations for stakeholders across the pain therapeutics continuum. For manufacturers that rely on globalized supply chains, tariff-related cost increases have prompted granular re-evaluations of sourcing decisions, input substitution, and manufacturing footprints. In many cases, companies responded by increasing inventory buffers, shifting critical components to alternative, lower-cost sourcing countries, or investing in nearshoring initiatives to reduce exposure to tariff volatility.

These operational adjustments have had secondary effects on product development timelines and commercial strategies. Firms prioritized investments that offered resilience or differentiated value, such as advanced delivery systems or device-drug combinations less vulnerable to commodity price swings. Contract negotiations with distributors and payers now routinely include tariff mitigation clauses and pass-through mechanics, which has influenced pricing discussions and reimbursement negotiations.

At the clinical level, the tariff environment reinforced the importance of cost-effective therapeutic options and accelerated payer interest in therapies that deliver demonstrable reductions in utilization of high-cost services. As a result, companies that can evidence total cost of care benefits or that offer integrated service models gained negotiating leverage. Overall, the tariff context has elevated operational agility and supply chain transparency into core competitive capabilities for industry participants.

A multi-dimensional segmentation framework integrates drug classes, delivery modes, indications, distribution channels, and end-user contexts to reveal targeted opportunities

A nuanced segmentation lens is essential for understanding where clinical opportunity and commercial traction intersect in the pain therapeutics space. Based on drug class, the field spans adjuvant analgesics, local anesthetics, neuropathic pain agents, nonsteroidal anti-inflammatory drugs, and opioids, with the neuropathic pain agents further divided into anticonvulsants and antidepressants, the nonsteroidal category bifurcated into Cox-2 inhibitors and traditional NSAIDs, and the opioid class separated into strong and weak opioids. Each drug-class subsegment exhibits distinct efficacy, safety, and regulatory profiles that shape prescriber preference and reimbursement considerations.

Based on route of administration, therapeutic delivery channels include oral, parenteral, topical, and transdermal options, while the parenteral route itself is differentiated across intramuscular, intravenous, and subcutaneous modalities. Delivery format influences adherence, onset of action, and suitability for ambulatory versus inpatient settings, and it informs the design of clinical trials and real-world evidence programs.

Based on indication, the therapeutic landscape covers acute pain, cancer pain, chronic pain, inflammatory pain, and neuropathic pain, with chronic pain further dissected into low back pain, neuropathic chronic pain, osteoarthritis, and rheumatoid arthritis. Indication-specific outcomes, patient-reported measures, and comorbidity profiles dictate both clinical development priorities and commercialization tactics.

Based on distribution channel, products reach patients through offline and online pathways, with digital pharmacies and telehealth-enabled dispensing changing access dynamics. Finally, based on end user, the marketplace serves ambulatory surgical centers, home care settings, and hospitals, with home care settings subdivided into hospice care and patient home, and hospitals separated into private and public institutions. These end-user distinctions determine procurement cycles, formulary decisions, and required supporting services, and they influence the optimal commercial model for launch and scale.

Regional payer structures, regulatory diversity, and care delivery models create distinct commercial pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on product strategy, regulatory pathways, and commercialization approaches within pain management therapeutics. The Americas continue to exhibit advanced adoption of opioid stewardship policies, widespread integration of multimodal perioperative programs, and significant private payer influence on coverage and reimbursement decisions, creating an environment where demonstrable real-world outcomes and economic value resonate strongly with purchasers.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse payer architectures require adaptable market access strategies and local evidence generation to support formulary inclusion. Reimbursement rules in several jurisdictions emphasize conservative use of high-cost interventions and favor established nonpharmacologic care pathways, prompting companies to design localized value dossiers and to pursue partnerships with regional health systems.

Across Asia-Pacific, rapid uptake of innovative delivery platforms, expanding ambulatory care infrastructure, and growing investment in home-based services are fostering new channels for distribution and patient engagement. The region also presents opportunities to leverage manufacturing scale and cost efficiencies, though companies must navigate varied regulatory timelines and local clinical practice patterns. Together, these regional contours demand differentiated go-to-market blueprints that align clinical evidence, pricing strategies, and stakeholder engagement to regional payer and provider realities.

A collaborative competitive landscape where pharmaceutical incumbents, specialty innovators, device partners, and digital entrants converge to create integrated therapeutic solutions

Competitive dynamics in the pain therapeutics domain are defined by a mix of legacy pharmaceutical players, specialty developers, device manufacturers, and digital health entrants, each bringing different strengths to market. Incumbent pharmaceutical companies leverage broad commercialization networks, established relationships with payers and providers, and deep clinical trial expertise, but they face pressure to innovate beyond traditional opioid-centric portfolios.

Specialized innovators focus on novel mechanisms of action, advanced delivery systems, and combination product strategies that seek to differentiate on efficacy, safety, or convenience. These firms often pursue strategic alliances with device makers or digital health firms to create integrated solutions that support adherence and remote monitoring. Device manufacturers are increasingly partnering with pharmaceutical developers to co-develop drug-device combinations that extend patent life and improve therapeutic precision.

Digital health companies are introducing behavioral therapies, remote monitoring, and AI-enabled pain-tracking tools that complement pharmacologic regimens and provide meaningful patient-reported outcome data. Collaboration, rather than pure competition, is emerging as a sustainable model; alliances between large manufacturers and agile disruptors enable acceleration of time-to-market while de-risking innovation. Overall, companies that combine robust clinical evidence, differentiated delivery, and clear value propositions for payers and providers are most likely to sustain commercial momentum.

Actionable strategies to strengthen evidence generation, supply chain resilience, integrated product design, and tailored market access for sustained competitive advantage

Industry leaders seeking to navigate the current pain therapeutics environment should pursue evidence-led, stakeholder-centric strategies that align clinical development with commercial imperatives. First, prioritize generation of pragmatic real-world evidence and patient-centered outcomes that demonstrate functional improvement and reductions in downstream resource utilization, thereby meeting the dual needs of clinicians and payers. Align study designs with the endpoints that matter to health systems to accelerate formulary acceptance and clinical adoption.

Second, diversify supply chains and consider onshoring or regional manufacturing to reduce exposure to tariff and trade volatility while ensuring consistent product availability. Transparency in supplier relationships and proactive inventory management will strengthen contracting positions with large health systems. Third, invest in hybrid product models that pair pharmacologic therapies with digital tools or device components to improve adherence, enable remote titration, and produce richer longitudinal data for value demonstration.

Fourth, tailor market access approaches to regional payer architectures and care delivery models, building localized value dossiers and forming partnerships with provider networks for pilot deployments. Finally, cultivate cross-sector collaborations and licensing arrangements to share development risk and accelerate commercialization capacity, focusing on segments where differentiated clinical benefits and durable reimbursement pathways are plausible.

A rigorous mixed-methods research approach combining expert interviews, literature synthesis, and triangulated analyses to validate strategic insights and implications

This report synthesizes insights derived from a mixed-methods research framework combining primary and secondary approaches to ensure robust, triangulated findings. Primary inputs include structured interviews with clinical thought leaders, payers, hospital procurement executives, and commercial leaders, as well as advisory panel discussions that validated key thematic trends. These qualitative inputs were complemented by an extensive review of peer-reviewed literature, regulatory guidance, clinical trial registries, technology white papers, and public policy statements to construct an up-to-date evidence base.

Analytical methods included thematic coding of expert interviews to identify recurring strategic priorities, scenario mapping to explore potential operational responses to tariff shifts, and comparative analysis across delivery formats and indications to surface niche opportunities. The segmentation framework was validated through cross-referencing procurement practices and formulary policies across hospital, ambulatory, and home care settings. Limitations of the methodology include the evolving nature of regulatory guidance and the variability of regional reimbursement rules, which were addressed by including time-bound caveats and by recommending continuous surveillance for policy changes.

Throughout, data integrity was prioritized via source triangulation and expert validation to ensure that conclusions reflect a balanced and pragmatic view of the industry landscape.

Conclusive synthesis emphasizing evidence-driven differentiation, adaptive commercial models, and collaborative innovation to secure long-term adoption and value realization

In summary, the pain management therapeutics landscape is at an inflection point characterized by clinical innovation, heightened regulatory scrutiny, and a stronger emphasis on value. The shift toward multimodal care, the rise of digital and device-enabled adjuncts, and the need for resilient supply chains have together created a more complex but opportunity-rich environment for product developers and service providers. Success will depend on the ability to generate meaningful real-world evidence, to craft compelling value propositions for diverse payers, and to deploy adaptive commercial models that reflect regional care delivery realities.

Companies that embrace collaborative development models, prioritize patient-centric outcomes, and invest in operational flexibility will be better positioned to capture opportunity and mitigate risk. The implications extend across the product lifecycle, from clinical development and regulatory strategy to manufacturing and post-market support. Ultimately, the landscape rewards organizations that can translate clinical differentiation into demonstrable improvements in patient function and health system performance, thereby securing sustainable adoption and long-term relevance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of virtual reality based therapies for chronic neuropathic pain management
  • 5.2. Integration of wearable biosensing patches for continuous postoperative pain monitoring
  • 5.3. Development of personalized gene therapy approaches targeting inflammatory pain pathways
  • 5.4. Increasing use of digital health platforms to deliver cognitive behavioral therapy for pain
  • 5.5. Growth in minimally invasive focused ultrasound applications for musculoskeletal pain relief
  • 5.6. Surge in approval of long acting non opioid injectable formulations for osteoarthritis pain
  • 5.7. Emergence of cannabinoid receptor modulators designed for targeted neuropathic pain alleviation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pain Management Therapeutics Market, by Drug Class

  • 8.1. Adjuvant Analgesics
  • 8.2. Local Anesthetics
  • 8.3. Neuropathic Pain Agents
    • 8.3.1. Anticonvulsants
    • 8.3.2. Antidepressants
  • 8.4. Nonsteroidal Anti-Inflammatory Drugs
    • 8.4.1. Cox-2 Inhibitors
    • 8.4.2. Traditional NsaiDs
  • 8.5. Opioids
    • 8.5.1. Strong Opioids
    • 8.5.2. Weak Opioids

9. Pain Management Therapeutics Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Parenteral
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
    • 9.2.3. Subcutaneous
  • 9.3. Topical
  • 9.4. Transdermal

10. Pain Management Therapeutics Market, by Indication

  • 10.1. Acute Pain
  • 10.2. Cancer Pain
  • 10.3. Chronic Pain
    • 10.3.1. Low Back Pain
    • 10.3.2. Neuropathic Chronic Pain
    • 10.3.3. Osteoarthritis
    • 10.3.4. Rheumatoid Arthritis
  • 10.4. Inflammatory Pain
  • 10.5. Neuropathic Pain

11. Pain Management Therapeutics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Pain Management Therapeutics Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Care Settings
    • 12.2.1. Hospice Care
    • 12.2.2. Patient Home
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals

13. Pain Management Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pain Management Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pain Management Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Johnson & Johnson
    • 16.3.2. Pfizer Inc.
    • 16.3.3. Novartis AG
    • 16.3.4. Bayer AG
    • 16.3.5. GlaxoSmithKline plc
    • 16.3.6. Sanofi S.A.
    • 16.3.7. Teva Pharmaceutical Industries Ltd.
    • 16.3.8. Endo International plc
    • 16.3.9. Mallinckrodt plc
    • 16.3.10. AstraZeneca plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PAIN MANAGEMENT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PAIN MANAGEMENT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PAIN MANAGEMENT THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CANCER PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MAR